Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| NC1-H5254 | Human | Human NCAM-1 / CD56 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified) |  |
|
|
| NC1-M52H4 | Mouse | Mouse NCAM-1 / CD56 Protein, His Tag |  |
|
|
| NC1-HF2H5 | Human | FITC-Labeled Human NCAM-1 / CD56 Protein, His Tag |  |
|
|
| NC1-HF256 | Human | FITC-Labeled Human NCAM-1 / CD56 Protein, Fc Tag |  |
|
|
| NC1-H82E3 | Human | Biotinylated Human NCAM-1 / CD56 Protein, His,Avitag™ (MALS verified) |  |
|
|
| NC1-H5253 | Human | Human NCAM-1 / CD56 Protein, Fc Tag (MALS verified) |  |
|
|
| NC1-H5223 | Human | Human NCAM-1 / CD56 Protein, His Tag (MALS verified) |  |
|
|
Immobilized Anti-NCAM-1 Antibody, Human IgG1 at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human NCAM-1, Fc Tag (Cat. No. NC1-HF256) with a linear range of 0.08-0.625 μg/mL (QC tested).
The purity of Human NCAM-1 Protein, Llama IgG2b Fc Tag (Cat. No. NC1-H5254) is more than 90% and the molecular weight of this protein is around 245-285 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Leukemia; Ovarian Neoplasms; Rhabdomyosarcoma; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Multiple Myeloma; Sarcoma, Synovial; Neurofibrosarcoma; Neuroblastoma; Pulmonary Blastoma | Details |
| CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
| GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
| DXC-006 | DAC-006; DXC-006 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Hematologic Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
